We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · June 03, 2021

Impact of Treatment Delay on Survival Outcomes for Patients With Muscle-Invasive Bladder Cancer

Clinical Genitourinary Cancer


Additional Info

Disclosure statements are available on the authors' profiles:

Clinical Genitourinary Cancer
Management of Muscle-Invasive Bladder Cancer During a Pandemic: Impact of Treatment Delay on Survival Outcomes for Patients Treated With Definitive Concurrent Chemoradiotherapy
Clin Genitourin Cancer 2021 Feb 01;19(1)41-46.e1, BW Fischer-Valuck, JM Michalski, JG Harton, A Birtle, JP Christodouleas, JA Efstathiou, VK Arora, EH Kim, EM Knoche, RK Pachynski, J Picus, YJ Rao, M Reimers, BJ Roth, P Sargos, ZL Smith, MS Zaghloul, HA Gay, SA Patel, BC Baumann

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading